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Abstract
Pathogenic gene fusions have been identified in several histologic types of salivary gland
neoplasia, but not previously in acinic cell carcinoma (AcCC). To discover novel gene
fusions, we performed whole-transcriptome sequencing surveys of three AcCC archival
cases. In one specimen we identified a novel HTN3-MSANTD3 gene fusion, and in
another a novel PRB3-ZNF217 gene fusion. The structure of both fusions was consistent
with the promoter of the 5’ partner (HTN3 or PRB3), both highly expressed salivary gland
genes, driving overexpression of full-length MSANTD3 or ZNF217. By fluorescence in situ
hybridization of an expanded AcCC case series, we observed MSANTD3 rearrangements
altogether in 3 of 20 evaluable cases (15%), but found no additional ZNF217 rearrange-
ments. MSANTD3 encodes a previously uncharacterized Myb/SANT domain-containing
protein. Immunohistochemical staining demonstrated diffuse nuclear MSANTD3 expres-
sion in 8 of 27 AcCC cases (30%), including the three cases with MSANTD3 rearrange-
ment. MSANTD3 displayed heterogeneous expression in normal salivary ductal
epithelium, as well as among other histologic types of salivary gland cancer though with-
out evidence of translocation. In a broader survey, MSANTD3 showed variable expression
across a wide range of normal and neoplastic human tissue specimens. In preliminary
functional studies, engineered MSANTD3 overexpression in rodent salivary gland epithe-
lial cells did not enhance cell proliferation, but led to significant upregulation of gene sets
involved in protein synthesis. Our findings newly identify MSANTD3 rearrangement as a
recurrent event in salivary gland AcCC, providing new insight into disease pathogenesis,
and identifying a putative novel human oncogene.
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Introduction
In cancers, chromosomal translocations and rearrangements can create gene fusions, resulting
in the effective overexpression of full-length cancer genes or producing chimeric oncoproteins
[1, 2]. Gene fusions were originally considered hallmarks of hematopoietic and mesenchymal
cancers, but more recently have been reported in a wide range of epithelial cancer types [2].
Identifying and characterizing gene fusions have provided new molecular insight into disease
pathogenesis. Moreover, gene fusions have refined the diagnosis and classification of cancers,
and have proven to be effective targets for molecularly-directed therapy. Examples include the
classic BCR-ABL fusion in chronic myelogenous leukemia [3], and more recently, EML4-ALK
in lung cancer [4].
Salivary gland neoplasms comprise a collection of at least 30 distinct histopathologic sub-
types, including malignant epithelial tumors (e.g. acinic cell carcinoma, adenoid cystic carci-
noma, mucoepidermoid carcinoma, and salivary duct carcinoma) and benign epithelial
lesions (e.g. pleomorphic adenoma, basal cell adenoma, oncocytoma, myoepithelioma, and
Warthin tumor). Developing mainly in the parotid gland, these diagnoses together account for
approximately 6% of all head and neck tumors [5]. Over the past years, recurrent gene fusions
have been identified in several different salivary gland neoplasms [6–8], including PLAG1
fusions (most often CTNNB1-PLAG1) and HMGA2 rearrangements in pleomorphic adenoma,
CRTC1-MAML2 fusion in mucoepidermoid carcinoma, MYB-NFIB (or MYBL1-NFIB [9, 10])
fusion in adenoid cystic carcinoma, ETV6-NTRK3 fusion in mammary analogue secretory car-
cinoma of the salivary gland, and EWSR1-ATF1 fusion in hyalinizing clear cell carcinoma.
These fusions, impacting cell signaling pathways and cell-cycle regulation, inform neoplastic
mechanisms, provide molecular biomarkers for refined diagnosis, and may suggest new
opportunities for therapy. Whether other salivary gland neoplasms also harbor recurrent gene
fusions has remained an open question.
Acinic cell carcinoma (AcCC) of the salivary gland is a malignant epithelial neoplasm
named for its characteristic acinic cell differentiation [11]. AcCC accounts for approximately
5–11% of all salivary gland carcinomas and is considered as a low-grade malignancy, with a
five-year disease-specific survival rate of 91% and a lifetime disease-associated death rate of
16% [12, 13]. Little is known about the pathogenesis of AcCC. Furthermore, ancillary tests and
the immunoprofile of AcCC are non-specific and thus, diagnosis is made based primarily on
morphologic criteria.
Here, to discover pathogenic gene fusions in AcCC, we performed whole transcriptome
analysis of three prototypic cases. We report the identification of a novel gene fusion,
HTN3-MSANTD3, and recurrent rearrangements of MSANTD3 in 16% of AcCC. A hitherto
unstudied gene, we also here surveyed MSANTD3 expression across a diverse set of human tis-
sues and neoplasias, and carried out preliminary studies of its function.
Materials and methods
Tissue specimens
Salivary gland acinic cell carcinoma specimens were identified by an electronic search of the
Stanford University Department of Pathology archives. In all, we retrieved formalin-fixed
paraffin-embedded (FFPE) blocks for 27 cases dating between 1997 and 2014. Hematoxylin
and eosin (H&E) stained tissue sections were reviewed by a pathologist (R.B.W) to confirm
the diagnosis. Three AcCC cases were used for the RNA-seq studies, while all 27 were incor-
porated into a tissue microarray (TMA). All existing archived tissue specimens reported in
this publication were used with Stanford University Institutional Review Board approval
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Transcriptome sequencing (RNA-seq)
RNA-seq of FFPE specimens was done as previously reported [14]. Briefly, FFPE blocks were
sectioned (10μM thickness), RNA isolated using the Allprep RNA/DNA FFPE kit (Qiagen),
and RNA quality verified by Agilent Bioanlyzer. Sequencing libraries (150 bp average insert
size) were then prepared from 100 ng of rRNA-depleted RNA using TruSeq RNA Sample
Preparation Kit v2 (Illumina), with four indexed libraries loaded per flow-cell lane. Paired-end
75-bp sequencing was carried out on a HiSeq 2000 instrument (Illumina), with the three
AcCC libraries yielding 103–110 million sequencing reads. For discovery of gene fusions, evi-
denced by paired reads mapping to two different genes, and/or reads spanning predicted
fusion junctions, we used Chimeriscan [15], TopHat-Fusion [16], SnowShoes-FTD [17], and
deFuse [18] software. RNA-seq reads are available at GEO (accession GSE76354). Analysis of
publically-available The Cancer Genome Atlas (TCGA) RNA-seq data was done using Wan-
derer [19], a web-based interactive viewer.
Tissue microarrays
A TMA comprising 27 AcCC cases was constructed as previously described [20], using a man-
ual tissue arrayer (Beecher Instruments). Each case was represented by two 0.6mm cores. Ten
additional TMAs, covering other salivary gland tumor diagnoses as well as normal and neo-
plastic tissues from diverse anatomic sites, and together representing 1495 cases, were previ-
ously described [21, 22].
Fluorescence in situ hybridization
Identified gene rearrangements were validated in TMA tissue sections by “break apart” FISH
assay. Custom FISH probes for the MSANTD3 locus were generated from bacterial artificial
chromosomes (BAC) flanking MSANTD3, CTD-3186I20 Cy5 (telomeric) and CTD-2363K7
Cy3 (centromeric) (BACPAC Resources Center, Children’s Hospital Oakland Research Insti-
tute). Custom FISH probes for the ZNF217 locus were CTD-2552P20 Cy5 (telomeric) and
CTD-2511E9 Cy3 (centromeric). Break-apart FISH was done as previously described [22].
Briefly, TMA sections (6μm) were pretreated with citric acid buffer (pH 6.0). BACs were
directly labeled with either Cy5 or Cy3 (GE Healthcare Life Sciences) and then hybridized
using Vysis reagents and protocols. Slides were counterstained with 4,6-diamidino 2-phenylin-
dole for microscopy, and images captured using Ariol software (Applied Imaging). For each
case, 100 nuclei were evaluated and cases scored positive for rearrangement if30 breaks of
the two probes were present. Cases with poor FISH probe hybridization were considered une-
valuable, and excluded from subsequent analysis.
Immunohistochemistry
MSANTD3 protein expression was evaluated by immunohistochemistry using an anti-
MSANTD3 antibody (LS-C146308, 1:2400 dilution; LifeSpan Biosciences) and peroxidase-
based chromogenic staining (EnVision, Dako). All slides were uploaded to the Stanford Tissue
Microarray Database [23]. Cores were evaluated for nuclear staining and assigned a score of
strong (2), moderate (1), weak (+/-), negative (-), or uninterpretable/missing core (<100
evaluable nuclei). Strong staining was defined as intense staining in >30% or faint staining
MSANTD3 rearrangement in salivary gland acinic cell carcinoma
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in> 70% of nuclei; moderate staining as intense staining in 5–30% or faint staining in 30–70%
of nuclei; weak staining as intense staining in 0–5% or faint staining in 10–30% of nuclei; and
negative staining as faint staining in <10% of nuclei. Images were independently evaluated
using color segmentation software (GemIdent). Briefly, GemIdent was trained to recognize
positive and negative nuclei, and a percentage of positive staining was calculated. Since GemI-
dent could not readily distinguish intensities, the algorithm of< 9% staining was defined as
negative, 9–14% as weak, 14–26% as moderate, and >26% as strong. Discrepancies between
the manual and automated scores were further reviewed and a final score assigned by the
pathologist.
Phylogenetic studies
Conserved protein domains within MSANTD3 were identified by search of NCBI’s conserved
domain database [24]. Local protein sequence alignments were performed using the Multiple
Alignment Construction and Analysis Workbench (MACAW) [25]. Global protein sequence-
alignments were performed using ClustalX [26]. A boot-strapped phylogenetic tree was dis-
played with TreeView [27].
Cell culture studies
SMG-C6 cells, an SV40-immortalized rat submandibular salivary gland acinar cell line [28]
(kind gift of Dr. Margarita M. Vasquez, University of Texas Health Science Center at San
Antonio), were grown in DMEM/F12 media supplemented as described [29]. NIH-3T3
mouse embryo fibroblasts were obtained from the ATCC and grown in DMEM media sup-
plemented with 10% bovine calf serum. A human C-terminally Myc-tagged MSANTD3
cDNA ORF clone was obtained from Origene (SKU:RC203850), and then subcloned into
pLentiCMV-Puro (Addgene #17452) to create pLentiCMV-MSANTD3. pLentiCMV-M-
SANTD3 or empty vector control was packaged in 293T cells (ATCC) using ViraPower Len-
tiviral Packaging Mix (Thermo Fisher Scientific), and then transduced into SMG-C6 cells
and selected with 4 μg/ml puromycin. Western blotting was done as previously described
[30], using anti-MSANTD3 antibody (LS-C146308, 1:1000 dilution; LifeSpan Biosciences)
and anti-Myc antibody (9B11, 1:500 dilution; Cell Signaling). For cell proliferation assays,
cells were plated in 6-well plate wells (20,000 cells per well in triplicate) and cell proliferation
determined 1, 3 and 5 days later by Wst-1 assay (Roche). For contact-inhibition studies,
NIH-3T3 cells were transduced with pLentiCMV-MSANTD3, KRAS(V12) positive-control,
or empty vector control as above, and selected in 2 μg/ml puromycin. One million cells were
plated per 10 cm dish in triplicate, and 16 days later cells were fixed with methanol, stained
with 0.5% crystal violet (in 25% methanol), and then foci3 mm counted. For SMG-C6
transcriptome studies, RNA was isolated with RNeasy (Qiagen), and then the TruSeq RNA
Sample Preparation Kit v2 (Illumina) used to prepare barcoded-sequence libraries, which
were sequenced on an Illumina HiSeq2000 instrument (101bp paired reads) to 36–49 mil-
lion reads. Reads were aligned to the rat genome using DNAnexus, which also provided
reads per kilobase transcript per million mapped reads (RPKM). Non-expressed genes
(RPKM<1) were filtered, and gene RPKM ratios (MSANTD3/empty vector) calculated. Dif-
ferentially-expressed gene sets were then identified using Gene Set Enrichment Analysis
(GSEA) [31], with the ‘pre-ranked’ option and default settings. RNA-seq reads are available
at GEO (accession GSE76354).
MSANTD3 rearrangement in salivary gland acinic cell carcinoma
PLOS ONE | DOI:10.1371/journal.pone.0171265 February 17, 2017 4 / 18
Results
Transcriptome sequencing identifies novel gene fusions in acinic cell
carcinoma
As part of a broader transcriptome survey to discover novel oncogenic gene fusions or muta-
tions in less common cancer diagnoses that are available mainly as archived FFPE tissue blocks
[14], here we carried out whole-transcriptome sequencing of three prototypic AcCC cases.
Illumina sequencing libraries were constructed from rRNA-depleted total RNA, and Illumina
paired-end sequencing (75bp x 2) was done to a depth of 103–110 million reads per case. To
discover gene fusions, evidenced by paired sequencing reads mapping to two different genes
and/or reads spanning predicted fusion junctions, we used four different software tools: Chi-
meriscan [15], TopHat-Fusion [16], SnowShoes-FTD [17], and deFuse [18]. All four algo-
rithms identified a total of two fusion genes, both novel, and one in each of two different
AcCC cases.
The first novel chimeric transcript resulted from fusion of noncoding exon 1of Histatin 3
(HTN3; cytoband 4q13.3) to exon 2 (the first coding exon) of Myb/SANT-like DNA-binding
domain contain 3 (MSANTD3; cytoband 9q31.1) (Fig 1A). The fusion junction was supported
by 51 junction-spanning reads (with 28 unique reads; S1 Fig). Consequent to the rearrange-
ment, the promoter of a highly-expressed salivary gland gene, the microbial peptide precursor
HTN3 [32], ostensibly drives overexpression of MSANTD3, an uncharacterized protein har-
boring a Myb/SANT-like domain characteristic of the MYB oncoprotein and SANT family
proteins [33].
The second chimera resulted from fusion of exon 2 of Proline-rich protein BstNI subfamily 3
(PRB3; cytoband 12p13.2) to exon 2 (the first coding exon) of Zinc finger protein 217 (ZNF217;
cytoband 20q13.2) (Fig 1B). The fusion junction was supported by 78 junction-spanning reads
(with 36 unique reads; S2 Fig). The rearrangement results in the promoter of another highly-
expressed salivary gland gene, PRB3 [34], possibly driving overexpression of ZNF217, a
reported oncoprotein in several cancer types [35]. However, the start codon (ATG) of ZNF217
is out of frame relative to the normal PRB3 open reading frame (Fig 1B), and therefore genera-
tion of ZNF217 protein would necessitate internal initiation of translation.
FISH analysis reveals recurrent MSANTD3 rearrangement in acinic cell
carcinoma
To validate MSANTD3 rearrangement in the index case, and to identify possible MSANTD3
rearrangements in additional AcCC cases, we developed a ‘break-apart’ FISH assay. In this
assay, differentially fluorescently-labeled FISH probes flanking the MSANTD3 locus would
appear co-localized in normal interphase nuclei, but physically-separated in nuclei harboring
allelic rearrangement at the locus. We carried out break-apart FISH on a tissue microarray
comprising 27 different AcCC cases, including the three cases evaluated by RNA-seq. In all, 3
of the 20 evaluable cases (including the index case) exhibited break-apart rearrangement of
MSANTD3 locus (Table 1 and Fig 2A–2C), validating the rearrangement in the index case, and
estimating the recurrence rate to be 15%. In all three FISH-positive cases, the rearrangement
was heterozygous (i.e. affecting only one MSANTD3 allele), consistent with a dominantly act-
ing oncogene. A fourth AcCC case showed isolated loss of the telomeric FISH probe (down-
stream of MSANTD3) (Table 1), a finding with uncertain expected impact on MSANTD3
expression.
We developed an analogous ‘break-apart’ FISH assay for the ZNF217 locus. In all, 13 of the
27 cases were evaluable (i.e. sufficient FISH hybridization signal), and only the index case
MSANTD3 rearrangement in salivary gland acinic cell carcinoma
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scored positive for ZNF217 (heterozygous) locus rearrangement (Fig 2D). Thus, while we vali-
dated rearrangement in the index case, we did not find evidence for recurrent rearrangement.
As such, our subsequent studies focused on the recurrent MSANTD3 rearrangement.
MSANTD3 is highly expressed in a subset of acinic cell carcinomas
In the index case, the HTN3 promoter ostensibly drives the overexpression of a chimeric tran-
script encoding full-length MSANTD3 protein. To evaluate MSANTD3 protein expression, we
carried out immunohistochemistry on the above TMA. Of 27 AcCC cases, 8 (30%) were
strongly positive for MSANTD3 diffuse nuclear-staining (the expected cellular compartment
for Myb/SANT domain-containing proteins) (Table 1 and Fig 2E–2G). The 8 IHC strongly-
positive cases included all 3 cases with MSANTD3 rearrangement, a statistically-meaningful
enrichment (P = 0.02; two-tailed Fisher’s exact test). Also noteworthy, 7 of the 27 AcCC cases
Fig 1. Novel genes fusions in acinic cell carcinoma. (A) Predicted structure of the HTN3-MSANTD3
fusion gene. Exon 1 (non-coding) of HTN3 is fused to the exon 2 (first coding exon) of MSANTD3, leading to
predicted overexpression of full-length MSANTD3 protein (translation start site is indicated). Fusion junction-
spanning sequence reads are shown in S1 Fig. (B) Predicted structure of the PRB3-ZNF217 gene fusion.
Here, exon 2 (coding) of PRB3 is fused to exon 2 (first coding) of ZNF217, possibly leading to the
overexpression (by internal initiation of translation) of full-length ZNF217 protein. Fusion junction-spanning
sequence reads are shown in S2 Fig.
doi:10.1371/journal.pone.0171265.g001
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demonstrated extensive lymphocytic infiltration (a common finding in AcCC; [36]), and all 7
were among the 18 cases that expressed MSANTD3 to some degree (Table 1) (P = 0.06, two-
tailed Fisher’s exact test); albeit, all 7 cases were FISH-negative for MSANTD3 rearrangement.
The meaning of this association is unclear.
MSANTD3 expression varies across other neoplasias of the salivary
gland and diverse tissue types
Since MSANTD3 was an unstudied protein, we sought to characterize its expression across a
wider array of benign and malignant tissues. Towards this goal, we carried out IHC staining of
11 previously described TMAs, altogether comprising 1293 evaluable cases representing nor-
mal and neoplastic tissues of the salivary gland, brain, head and neck, gastrointestinal, cardio-
vascular, respiratory, immunologic, endocrine, integumentary and musculoskeletal systems.
Of these, 258 cases were of salivary origin, and the remaining 1035 cases were from other
organ systems and included 235 normal tissues, 70 embryonic tissues, 55 benign or pre-malig-
nant tissues, 40 benign neoplasms and 635 malignant neoplasms.
Table 1. Acinic cell carcinoma cases.
Casea MSANTD3 FISH MSANTD3 IHC score ZNF217 FISH RNA-seq fusion Lymphocytic infiltrateb
1 BREAK APART Strong Normal HTN3-MSANTD3 No
2 BREAK APART Strong No
3 BREAK APART Strong No
4 Normal Strong YES
5 Normal Strong YES
6 Normal Strong No
7 Strong No
8 Not scorable Strong BREAK APART PRB3-ZNF217 No
9 Normal Moderate Normal YES
10 Normal Moderate YES
11 Normal Moderate Normal No
12 Not scorable Moderate Normal No
13 Normal Weak Normal YES
14 Normal Weak Normal YES
15 Normal Weak Normal YES
16 Normal Weak Normal No
17 Normal Weak No
18 Not scorable Weak Normal No
19 Loss of red signal Negative Normal No
20 Normal Negative Normal None identified No
21 Normal Negative Normal No
22 Normal Negative No
23 Normal Negative No
24 Normal Negative No
25 Not scorable Negative Normal No
26 Negative No
27 Negative No
aOrdered by MSANTD3 IHC score
bDefined as lymphocytic infiltrate greater than 30%
doi:10.1371/journal.pone.0171265.t001
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With respect to the salivary gland tissues (Table 2 and Fig 3A and 3B), MSANTD3 was
expressed in normal salivary gland ductal cells to varying degrees. However, acinar cells were
most often entirely negative (24/33 cases), or displayed weak staining (5/33) and at most mod-
erate staining (4/33). While 51% of salivary specimens (benign and malignant) tested were
void of any MSANTD3 staining, strong MSANTD3 expression was observed in a substantial
subset of mucoepidermoid carcinomas (5/25, 20%) and adenosquamous carcinomas (3/5,
60%). FISH performed on 120 of the salivary gland neoplastic cases (other than AcCC) identi-
fied no additional MSANTD3 rearrangements. To exclude the possibility that our MSANTD3
antibody might cross react with MYB (itself rearranged in a subset of salivary gland tumors),
IHC-staining for MYB was performed and compared with MSANTD3 staining across 172
cases and no correlation was observed (data not shown).
Beyond the salivary gland (Table 3 and Fig 3C–3P), MSANTD3 was expressed in a small
subset of normal cell types and in many neoplasms. In normal tissues, expression was identi-
fied in spermatogonia and early spermatocytes, the parietal cells of stomach, tubular and parie-
tal epithelial cells of the kidney, cortical cells of the adrenal gland, uterine endometrium and
the glandular epithelium of the prostrate.
Expression in carcinoma was more prominent, with strong expression in multiple gonad-
ally-derived carcinomas, adenocarcinomas of the stomach, lung, pancreas, endometrium, and
bladder, as well as, papillary thyroid carcinoma, hepatocellular carcinoma, urothelial carci-
noma and a subset of invasive breast cancers. In contrast, MSANTD3 expression was rarely
observed in normal and neoplastic tissues of the brain, head and neck region, esophagus,
integument, musculoskeletal system, lymphovascular system, small bowel and large bowel.
Fig 2. Evaluation of MSANTD3 rearrangement and protein expression in accinic cell carcinoma tissue sections. (A-C) Break-apart
FISH assay of MSANTD3 locus rearrangement; green FISH probe is flanking centromeric and red FISH probe is flanking telomeric to
MSANTD3. Note positive rearrangement (evidenced by physically-separated green and red signals, arrows) in AcCC case (A). AcCC case
(B) is negative for the rearrangement (i.e., signals co-localize), as is observed in normal salivary gland control (C). (D) Break-apart FISH
assay of ZNF217 rearrangement, confirming the rearrangement in the index case. (E-G) Corresponding MSANTD3 immunostaining of the
above cases. Note the strong nuclear MSANTD3 staining (E) corresponding to the FISH-positive rearranged specimen.
doi:10.1371/journal.pone.0171265.g002
MSANTD3 rearrangement in salivary gland acinic cell carcinoma
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Also, tubularly-derived carcinomas of the kidney did not exhibit staining, an interesting find-
ing considering the prominent expression in normal kidney tubules. Analysis of publicly-avail-
able The Cancer Genome Atlas (TCGA) RNA-seq data also showed varied MSANTD3
transcript levels across cancer types, with several exhibiting significantly higher expression in
cancer compared to matched normal tissue (S3 Fig).
In addition, because we had stained a large number of breast cancers and had clinical out-
come parameters on these specimens, we attempted to identify clinicopathologic correlates.
We found no correlation between MSANTD3 expression and ER or HER2 status, nor did we
identify a significant correlation with survival (P = 0.18, log-rank test).
MSANTD3 protein is highly conserved among tetrapods
Because little was known about MSANTD3, we also examined its evolutionary conservation to
infer function and to identify possible relevant model organisms. Human MSANTD3 com-
prises 275 amino acids, with a predicted molecular weight of 32 kD. A search for conserved
protein domains identified only the Myb/SANT domain within the N-terminus (Fig 4A).
Analysis of amino acid conservation across species revealed MSANTD3 to be highly conserved
in mammals (human), birds (chicken), reptiles (python), and amphibians (frog), but far less
conserved in ray-finned fish (cichlid) (Fig 4B–4D). Even more distantly related MSANTD3-
like proteins are present in invertebrates (Ciona, sea urchin, and fruit fly). There appeared to
be no MSANTD3-related gene in nematode worms, plants, fungi, or bacteria. The MSANTD3
homolog in cichlids (bony fish) is about as distant from other vertebrates as is the insect gene.
Other fish (e.g. fugu and zebrafish) have even more distantly related genes. Interestingly, the
Table 2. MSANTD3 immunostaining of salivary gland benign and malignant specimens.
Immunostaining score (number of cases, %)
Salivary gland Strong % Moderate % Weak % Negative % Total
Normal Adult 0 0% 4 12% 5 15% 24 73% 33
Embryonic 0 0% 0 0% 0 0% 2 100% 2
Benign Pleomorphic Adenoma 2 4% 5 10% 11 22% 32 64% 50
Basal Cell Adenoma 0 0% 0 0% 3 33% 6 67% 9
Monomorphic Adenoma 0 0% 0 0% 0 0% 1 100% 1
Oncocytoma 1 9% 2 18% 4 36% 4 36% 11
Oncocystic Hyperplasia 2 67% 0 0% 1 33% 0 0% 3
Oncocytic Cystadenoma 0 0% 0 0% 1 100% 0 0% 1
Myoepithelioma 0 0% 0 0% 1 17% 5 83% 6
Warthin Tumor 1 100% 0 0% 0 0% 0 0% 1
Malignant AcCC: MSANTD3 Rearrangement 3 100% 0 0% 0 0% 0 0% 3
AcCC: Normal MSANTD3 FISH 3 18% 3 18% 5 29% 6 35% 17
AcCC: MSANTD3 FISH not evaluable 2 29% 1 14% 1 14% 3 43% 7
Adenocarcinoma NOS 1 8% 1 8% 3 23% 8 62% 13
Adenoid Cystic Carcinoma 3 5% 13 22% 15 25% 28 47% 59
Adenosquamous Carcinoma 3 60% 0 0% 1 20% 1 20% 5
Basal Cell Adenocarcinoma 0 0% 0 0% 0 0% 1 100% 1
Mucoepidermoid 5 20% 8 32% 5 20% 7 28% 25
Myoepithelial 0 0% 1 20% 1 20% 3 60% 5
Salivary Duct Carcinoma 1 33% 2 67% 0 0% 0 0% 3
NOS 0 0% 1 33% 1 33% 1 33% 3
Total 27 10% 41 16% 58 22% 132 51% 258
doi:10.1371/journal.pone.0171265.t002
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coelacanth, a lobe-finned fish that is thought to be related to a common ancestor of all tetra-
pods [37], has an MSANT3 protein more similar to those of land vertebrates. Furthermore, the
vertebrate and coelacanth proteins share homologous regions outside of the N-terminal Myb/
SANT domain that are poorly conserved in other species.
MSANTD3 overexpression upregulates genes functioning in protein
synthesis
Recurrent rearrangement of MSANTD3 in AcCC, ostensibly driving overexpression of the
full-length MSANTD3 protein, combined with observed overexpression by IHC, strongly sug-
gested an oncogenic driver role in AcCC. To preliminarily characterize potential oncogenic
functions, we used lentiviral transduction to engineer MSANTD3 overexpression in cultured
cells, first using an immortalized rat submandibular salivary gland acinar cell line model [28],
SMG-C6. Overexpression of MSANTD3 in SMG-C6 cells, confirmed by western blot (Fig 5A)
Fig 3. Representative images of MSANTD3 immunostaining in select tissues. (A) Normal salivary tissue, (B) Mucoepidermoid carcinoma,
(C) Normal breast tissue, (D) Invasive breast carcinoma, not otherwise specified, (E) Normal bladder, (F) Urothelial carcinoma, (G) Normal
prostate, (H) Normal stomach, (I) Normal kidney, (J) Fetal kidney, (K) Normal liver, (L) Hepatocellular carcinoma, (M) Normal testicle, (N)
Seminoma, (O) Testicular atrophy, and (P) Adrenal cortex. Images were acquired at 40x magnification.
doi:10.1371/journal.pone.0171265.g003
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Table 3. MSANTD3 immunostaining across diverse benign and neoplastic tissues.
Tissue MSANTD3 strong immunostaining (No. cases) Total No. cases % strongly positive
Testis Normal 14 14 100%
Atrophic/Immature 0 4 0%
Seminoma 19 22 86%
Teratoma 2 3 67%
Yolk Sac Tumor 4 4 100%
Embryonal Carcinoma 1 2 50%
Granulosa Cell Tumor 1 1 100%
Leydig Cell Tumor 0 1 0%
Adrenal Normal Cortex 14 22 64%
Adenoma 1 3 33%
Adrenocortical Carcinoma 1 2 50%
Pheochromocytoma 0 2 0%
Bladder Normal 0 7 0%
Embryonic 0 2 0%
Adenocarcinoma 2 3 67%
Uroethelial Carcinoma 3 14 21%
Breast Normal 0 7 0%
Invasive Ductal 4 11 36%
Invasive Lobular 2 3 67%
Invasive NOS 75 248 30%
Kidney Normal 11 13 85%
Embryo 0 5 0%
Oncocytoma 0 2 0%
Clear Cell Carcinoma 0 1 0%
Conventional Carcinoma 0 4 0%
Papillary Carcinoma 0 4 0%
Liver Normal 0 11 0%
Hepatocellular 4 10 40%
Lung Normal 0 7 0%
Andenocarcinoma 8 14 57%
Ovary Normal 0 7 0%
Mucinous Carcinoma 2 3 67%
Clear Cell Carcinoma 3 4 75%
Serous Carcinoma 3 5 60%
Prostate Normal 3 6 50%
Adenocarcinoma 7 12 58%
Stomach Normal 3 10 30%
Adenocarcinoma 5 7 71%
Thyroid Normal 0 12 0%
Papillary Carcinoma 2 5 40%
Follicular Carcinoma 1 2 50%
Pancreas Normal 0 3 0%
Adenocarcinoma 1 2 50%
Ductal 2 3 67%
Uterus Endometrium 2 3 67%
Endometrial Carcinoma 7 11 64%
Leiomyosarcoma 0 5 0%
doi:10.1371/journal.pone.0171265.t003
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did not enhance cell proliferation (Fig 5B). Nor did overexpression of MSANTD3 in NIH-3T3
mouse embryo fibroblast cells result in lost contact-inhibition (assayed by focus formation; S4
Fig). To explore potential oncogenic phenotypes more broadly, we profiled transcriptomic
changes by RNA-seq in SMG-C6 cells overexpressing MSANTD3, compared to empty vector
control. By Gene Set Enrichment Analysis, MSANTD3 overexpression led to marked upregu-
lation of multiple gene sets associated with protein synthesis, including ‘ribosome’, ‘peptide
chain elongation’, and ‘translation’ (Fig 5C and S1 Table).
Fig 4. MSANTD3 structural domains and phylogenetic conservation. (A) Schematic depiction of MSANTD3 domains,
showing the location of the Myb/SANT-like domain within the N-terminus. (B) Schematic depiction of MSANTD3 MACAW
sequence alignments across species. Boxes indicate conserved blocks, while the shading indicates pair-wise scores relative to
human MSANTD3 with colors indicated in the key. Above, the horizontal black bar indicates the location of the conserved Myb/
MSANT domain found by NCBI search (Pfam 13873). (C) Actual MACAW alignment within the MYB/SANT region. (D)
Phylogenetic tree based on the global alignment made by ClustalX and visualized using Treeview software.
doi:10.1371/journal.pone.0171265.g004
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Discussion
Recurrent chromosomal rearrangements (and the resultant gene fusions) are known to charac-
terize other salivary gland tumors, but have not previously been reported in AcCC. Here, by
whole-transcriptome profiling of three AcCC cases, we discovered two novel fusion genes,
HTN-MSANTD3 and PRB3-ZNF217, and found that MSANTD3 locus rearrangements are
recurrent events observed in approximately 15% of AcCC cases. Furthermore, in a cell line
model, MSANTD3 overexpression led to the upregulation of genes involved in protein synthe-
sis, a cellular process often upregulated in cancer [38].
Notably, both novel fusion genes juxtapose a highly-expressed salivary gland gene (HTN3
or PRB3) to the full-length 3’ partner (MSANTD3 and ZNF217, respectfully), ostensibly driving
the overexpression of a chimeric transcript encoding the full-length 3’ fusion partner. For the
MSANTD3 rearrangement, we showed by immunostaining that MSANTD3 protein was in
fact highly expressed in all three cases with DNA rearrangement. Though we note that for the
other two cases with MSANTD3 rearrangement, the FFPE tissue blocks were exhausted and so
we did not have the opportunity to identify a putative 5’ fusion partner, which may or may not
Fig 5. MSANTD3 overexpression leads to the upregulation of genes involved in protein synthesis. (A) Overexpression of C-terminally
Myc-tagged MSANTD3 in SMG-C6 immortalized rat salivary gland epithelial cells, demonstrated by western blot using anti-MSANTD3
antibody (left) and anti-Myc tag antibody (right). Note, the observed band runs close to the calculated MW of the tagged protein (36 kD). (B)
MSANTD3 overexpression does not enhance cell proliferation, compared to empty vector control, quantified by Wst-1 assay. (C)
Transcriptome (RNA-seq) analysis of MSANTD3 overexpression identifies significant upregulation of gene sets associated with protein
synthesis. Gene Set Enrichment Analysis (GSEA) of the top gene set (‘KEGG Ribosome’) is shown; other significant gene sets are listed in S1
Table. Note, the early and positive upswing of the Enrichment profile reflects the early concentration of ribosome genes within the ranked list of
genes upregulated by MSANTD3 overexpression (compared to empty vector control).
doi:10.1371/journal.pone.0171265.g005
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also be HTN3. Notably, MSANTD3 protein was highly expressed in an additional 5 cases (for
30% of all cases), presumably upregulated by some mechanism other than genomic DNA
rearrangement.
With respect to the PRB3-ZNF217 fusion, ZNF217 is a zinc finger protein, a protein family
often functioning in transcriptional regulation through sequence-specific DNA binding [39].
ZNF217 was first characterized as the ‘driver’ oncogene amplified at 20q13.2 in breast cancer
[40], where it was found to promote cellular immortalization [40]. Since then, ZNF217 has
been implicated in ovarian and other cancer types, where it has been linked to diverse onco-
genic phenotypes including cell proliferation, survival, and invasion [35]. Although we have
not found ZNF217 rearrangements in other AcCC cases, and we have not demonstrated
ZNF217 protein expression, given its known oncogenic functions in other cancers it is intrigu-
ing to speculate a possible pathogenic role in a subset of AcCC cases.
In contrast, the recurrent nature of MSANTD3 gene rearrangements provides strong
genetic support for its pathogenic role. MSANTD3 is a previously unstudied gene, named for
harboring a protein domain with shared homology to the DNA-binding domains of MYB and
SANT-family proteins. MYB, the homolog of the avian myeloblastosis viral oncogene, func-
tions in normal hematopoiesis, and deregulated MYB expression has been linked with human
leukemia [41]. SANT is an acronym for switching-defective protein 3 (Swi3), adaptor 2
(Ada2), nuclear receptor co-repressor (N-CoR), transcription factor (TF)IIIB, with the four
proteins (and others since) found to share a conserved 50 amino-acid motif with the MYB
DNA-binding domain [33]. SANT domains are often present within subunits of chromatin-
remodeling and histone-modifying complexes [42]. It was initially hypothesized that all SANT
domains bind directly to DNA to enable their regulatory function. Structural and biochemical
evidence for this model has been provided in at least some cases [43–45]. However, it has also
been hypothesized that some SANT domains may bind directly to histones rather than to
DNA in order to regulate chromatin structure and function [42].
Interestingly, in a recent yeast two-hybrid screen to identify binding partners of methyl-
transferase enzymes [46], MSANTD3 (formerly known as C9orf30) was identified as one of
many putative binding partners of SUV39H1, itself a histone methyltransferase functioning in
establishing heterochromatin [47]. This finding implicates a possible role of MSANTD3 in
chromatin regulation, a function consistent with its having a Myb/SANT-like domain. We
also note that the observed immunostaining was predominantly nuclear, also consistent with a
role in chromatin dynamics. Nonetheless, detailed mechanistic studies will be necessary to elu-
cidate the protein’s normal function.
To further explore MSANTD3 biology, we carried out a broad immunostaining survey of
diverse normal and neoplastic tissues. Within the normal salivary gland, MSANTD3 generally
showed higher expression in ductal compared to acinar cells. MSANTD3 was also expressed in
a subset of other salivary gland neoplasias, though without evidence of locus rearrangement.
Other tissues that stained strongly included normal testis and kidney, and glandular tissues
including prostate and endometrium. Adenocarcimomas of diverse organ sites showed varied
staining, while squamous cell carcinomas, sarcomas, and lymphoid-derived neoplasias were
generally void of staining. The expression of MSANTD3 across diverse tissue types, as well as
its protein conservation down to amphibians, suggests an important cellular function(s).
Those functions, as well as possible roles in diseases beyond AcCC, remain to be explored.
To further characterize its pathogenic role in AcCC, we overexpressed MSANTD3 in
SMG-C6 immortalized rat salivary gland epithelial cells, a reasonable approximation of a nor-
mal cell type equivalent. MSANTD3 overexpression did not enhance cell proliferation. How-
ever, by expression profiling we found that its overexpression led, either directly or indirectly,
to marked upregulation of genes involved in translation of mRNA into proteins by ribosomes.
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This finding is intriguing because increased protein synthesis is a common feature of cancers
[38]. Oncoproteins including PI3-kinases, AKT kinase, ribosomal S6 kinase, and MYC are all
thought to act in large part by enhancing ribosome biogenesis and translation, to provide
needed new proteins for cell growth and proliferation [48, 49].
Of note, in a recent RNA-seq survey of cancer cell lines, a XRCC4-MSANTD3 in-frame
fusion was reported in SW780 bladder transitional cell carcinoma cells [50] (their Supplemen-
tary Table 8). However, that fusion was supported by only two sequencing reads, and the pre-
dicted fusion incorporates only the terminal exon of MSANTD3 and so would be missing the
highly-conserved Myb/SANT-like domain), and thus is unlikely to be functional.
Although the exact role(s) of MSANTD3 in AcCC oncogenesis remain to be determined, it
is also intriguing that MYB itself, which of course also harbors a Myb/SANT-like domain, is
part of a gene fusion that characterizes a different salivary gland tumor: MYB-NFIB in adenoid
cystic carcinoma. Perhaps this finding suggests a more general role of Myb/SANT-like DNA-
binding domain containing proteins in the normal biology and neoplastic conversion of sali-
vary epithelium.
From a diagnostic standpoint, several salivary gland neoplasias have been found to harbor
specific gene fusions that have proven to be useful biomarkers for differential diagnosis [6]. In
our study, we have identified MSANTD3 rearrangements in 15% of AcCC specimens, and in
no other salivary gland neoplasias. While its modest frequency in AcCC would limit its overall
diagnostic utility, finding MSANTD3 rearrangement (e.g. by FISH) in a diagnostically chal-
lenging case could nonetheless provide support for a diagnosis of AcCC. Whether MSANTD3
rearrangement and/or overexpression confer a distinct prognosis remains unanswered, and
need await studies on larger cohorts with clinical follow up.
In summary, by whole-transcriptome sequencing of archival AcCC cases and validation by
FISH, we have discovered novel gene fusions including a recurrent rearrangement of the previ-
ously uncharacterized gene MSANTD3. Functional studies implicate a role of MSANTD3 in
upregulating translation; however, the normal and tumorigenic mechanisms of this novel
putative oncogene await future investigation. Based on our studies, AcCC now joins other sali-
vary gland neoplasias in harboring specific chromosome rearrangements, and may ultimately
aid in the diagnosis and understanding of disease pathogenesis.
Supporting information
S1 Fig. HTN3-MSANTD3 junction-spanning reads. Shown are the 51 sequencing reads span-
ning the predicted HTN3-MSANTD3 junction, identified from the Chimeriscan analysis.
(PDF)
S2 Fig. PRB3-ZNF217 junction-spanning reads. Shown are the 78 sequencing reads spanning
the predicted PRB3-ZNF217 junction, identified from the Chimeriscan analysis.
(PDF)
S3 Fig. MSANTD3 transcript levels vary across cancer types. Plots display normalized tran-
script levels for cancer vs. normal samples, shown for those TCGA cancer types where there
are sufficient sample numbers to perform a statistical analysis (tumor vs. normal; Wilcoxon P-
value indicated). Plots assembled using Wanderer (see Methods).
(PDF)
S4 Fig. MSANTD3 overexpression does not lead to loss of contact-inhibition (focus forma-
tion). (A) Focus formation assay in NIH-3T3 cells transduced with pLenti-CMV-MSANTD3
(vs. pLenti-CMV empty vector control), or positive control pBABE-KRAS(V12) (vs. pBABE
empty vector control). Crystal violet stained foci were manually counted in triplicate 10cm
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plates; representative plates shown. (B) Graphical display of counted foci. Note, no foci
(>3mm) were observed following MSANTD3 overexpression.
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S1 Table. Canonical pathway gene sets found enriched by GSEA analysis.
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